Clinical Competition Candidate
ENTEREG
ENTEREG carries use-code patent, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 43 months away. Active clinical competition may compress the generic entry window.
LOE window
43months
to latest listed patent expiry (February 12, 2030)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (none)
Use-code patent (listed)
Patent count: 1
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 29
Phase 2/3 trials: 17
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: ALVIMOPAN
Applicant (NDA holder): CUBIST PHARMACEUTICALS INC
Confidence: High